Risk Minimisation Material: Myalepta (metreleptin) Healthcare Professional Guide
This highlights the main areas of risk with metreleptin treatment; hypoglycaemia with concomitant use of insulin and other anti-diabetics, acute pancreatitis with abrupt discontinuation, unplanned pregnancy due to improvement of hormonal dysfunction, and medication errors.
Source:
electronic Medicines compendium
SPS commentary:
A patient care guide, a patient dose information card, and a specialist prescriber guide have been produced in conjunction